Daniel L. Kranz

MedicineNeuroscienceBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Inhibition of amyloid beta oligomer accumulation by NU-9: A unifying mechanism for the treatment of neurodegenerative diseases”.

Inhibition of amyloid beta oligomer accumulation by NU-9: A unifying mechanism for the treatment of neurodegenerative diseases

Proceedings of the National Academy of Sciences(2025)10.1073/pnas.2402117122

N/A

0.269DataRank · unranked

5 citations

Raghad Nowar, Kirsten L. Viola, Weijian Huang, Sihang Zhou, Maíra A. Bicca +5 more

The therapeutic and diagnostic potential of amyloid β oligomers (AβOs) selective antibodies to treat Alzheimer’s disease

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.09.20.460817

N/A

0DataRank · unranked

0 citations

Maíra A. Bicca, Adrian M. Bebenek, Daniel L. Kranz, Vikas Nandwana, Emily A. Waters +11 more

The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease

Frontiers in Neuroscience(2022)10.3389/fnins.2021.768646

N/A

0DataRank · unranked

29 citations

Maíra A. Bicca, Adrian M. Bebenek, Daniel L. Kranz, Vikas Nandwana, Emily A. Waters +11 more

Identification of a glia‐associated amyloid β oligomer subtype and the rescue from reactive astrogliosis by inhibitor NU‐9

Alzheimer s & Dementia(2025)10.1002/alz.70968

N/A

0DataRank · unranked

1 citations

Omar de Leon Velez, Emel Ulupınar, P. Hande Özdi̇nler, Richard B. Silverman, William L. Klein +1 more